CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas Correspondence

  

Authors:	Fitzgerald, K. N.; Quesada, A. E.; von Keudell, G.; Raj, S.; Lewis, N. E.; Dogan, A.; Salles, G.; Palomba, M. L.
Title:	CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas
Keywords:	immunohistochemistry; adult; clinical article; human tissue; aged; middle aged; primary tumor; human cell; lenalidomide; cancer recurrence; case report; advanced cancer; cancer growth; flow cytometry; letter; antigen expression; phenotype; b lymphocyte; hospitalization; b cell lymphoma; germinal center; death; cancer cell; lymphoma cell; epitope; sepsis; imaging; follicular lymphoma; lymph node biopsy; cd19 antigen; cell surface; molecularly targeted therapy; fine needle aspiration biopsy; diffuse large b cell lymphoma; human; male; female; chimeric antigen receptor t-cell immunotherapy; masking; tafasitamab
Journal Title:	Leukemia and Lymphoma
Volume:	63
Issue:	3
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2022-01-01
Start Page:	751
End Page:	754
Language:	English
DOI:	10.1080/10428194.2021.1992622
PUBMED:	34949132
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121790784&doi=10.1080%2f10428194.2021.1992622&partnerID=40&md5=929b45394e0224efcdb66070e7c6f861
Notes:	Letter -- Export Date: 1 April 2022 -- Funding details: National Institutes of Health, NIH -- Funding details: National Cancer Institute, NCI, P30 CA008748, P50 CA192937 -- Funding details: Roche -- Funding details: Takeda Pharmaceuticals U.S.A., TPUSA -- Funding text 1: We would like to thank the Janice Stanton Fund for supporting this work. This work was supported in part through the NIH/NCI Cancer Center Support Grant [P30 CA008748] and MSK Lymphoma SPORE [P50 CA192937] (A.D.) and Farmer Family Foundation (A.D.). -- Funding text 2: Ahmet Dogan reports personal fees from Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Takeda, Roche, EUSAPharma, PeerView, and research support from Roche and Takeda. -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/197361